Search Results - therapeutics+%3e+oncology

114 Results Sort By:
Engineered Mucosal-Associated Invariant T (MAIT) Cells and Methods of Making and Using Thereof (UCLA Case No. 2024-055)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a novel platform and methodology for the production of mucosal-associated invariant T (MAIT) cells for therapeutic use in infectious diseases, autoimmune disorders, and cancer. BACKGROUND: Mucosal-associated invariant T (MAIT) cells are a subset of...
Published: 7/31/2025   |   Inventor(s): Lili Yang
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy, Therapeutics > Autoimmune
Improving Immunizations by Suppressing Autophagy in Cells (UCLA Case No. 2023-291)
UCLA researchers in the Department of Molecular, Cell and Developmental Biology have developed methods to suppress autophagy in cells to enhance immune response. These methods target local tumor sites instead of the whole body, thus reducing off-target effects and are applicable to a variety of cancer types, including solid and hematological tumors. BACKGROUND:...
Published: 7/17/2025   |   Inventor(s): Hilary Coller
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Fish Oil Plus Diet for Prostate Health (UCLA Case No. 2024-092)
UCLA researchers from the Department of Urology have identified a dietary intervention that may slow prostate cancer progression, offering a promising accessible, safe, and non-invasive approach to managing prostate health. BACKGROUND: Prostate cancer is the second most commonly diagnosed cancer in the United States and the fifth leading cause of death...
Published: 7/17/2025   |   Inventor(s): William Aronson
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Metabolism And Endocrinology
Reverse Engineering Vaccine Antigens (UCLA Case No. 2025-074)
UCLA researchers from the Department of Pediatrics-Allergy/Immunology have developed a novel platform to reverse engineer vaccine antigens for the prevention and treatment of infectious disease and cancer. BACKGROUND: Vaccines function by introducing antigens into a host to stimulate an immune response, providing protection against pathogens and certain...
Published: 7/17/2025   |   Inventor(s): Manish Butte
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Vaccines
Modified Hyaluronic Acid Hydrogels Containing Hyaluronidase for the Time‐Controlled and Targeted Release of anti-CTLA-4 and other Therapeutic Antibodies (UCLA Case No. 2016-526)
UCLA researchers from the Department of Medicine have developed a novel therapeutic platform for the administration of low-dose Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) antibody for cancer immunotherapy that synergizes with conventional PD-1 therapy while sparing systemic autoimmune toxicity. BACKGROUND: Immune checkpoint inhibitor (CPI)...
Published: 7/17/2025   |   Inventor(s): Michael Roth, Airi Harui
Keywords(s): Cancer Immunotherapy, Immunotherapy
Category(s): Platforms > Drug Delivery, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology
Analoging and SAR-Based Chemical Approach to Improve the Therapeutic Potency of Small-Molecule Inhibitors of Metastasis (UCLA Case No. 2024-116)
UCLA researchers in the Department of Molecular and Medical Pharmacology have developed an analoging and SAR-based chemical approach to generate novel, safe, and effective small-molecule inhibitors for preventing and treating cancer metastasis. BACKGROUND: The limited understanding of the biological mechanisms underlying metastasis in clear cell renal...
Published: 7/17/2025   |   Inventor(s): Lily Wu, Moe Ishihara, Robert Damoiseaux, Stuart Conway
Keywords(s): Cancer, Metastasis, Oncology (Small Molecules, Peptides and Antibodies), Small molecule therapeutics, small molecules
Category(s): Therapeutics > Oncology
KHK Inhibitors as Agents for the Treatment of Cancer and Metabolic Syndrome (UCLA Case No. 2021-222)
UCLA researchers in the Department of Chemistry and Biochemistry have synthesized novel KHK inhibitors that can result in anticancer drugs targeting cancer metabolism. BACKGROUND: Fructose is a naturally occurring sugar found in fruits and vegetables, and is an integral part of the human diet. In comparison to its functional isomer, glucose, which...
Published: 7/17/2025   |   Inventor(s): Heather Christofk, Michael Jung
Keywords(s): Cancer, cancer metabolism, metabolism, Oncology (Small Molecules, Peptides and Antibodies), small molecules
Category(s): Therapeutics > Oncology, Therapeutics > Metabolism And Endocrinology
Novel Strategy to Produce Bi-specific Chimeric Antigen Receptors (UCLA Case No. 2024-169)
Researchers in the Department of Medicine and the Department of Microbiology, Immunology and Molecular Genetics have created novel bi-specific chimeric antigen receptors. BACKGROUND: Chimeric antigen receptors (CARs) are synthetic receptors engineered to redirect T cells towards specific targets on other cells, typically using a single chain antibody....
Published: 7/17/2025   |   Inventor(s): Otto Yang
Keywords(s):  
Category(s): Therapeutics > Oncology
Small Molecules that Inhibit RNA Binding Protein IGF2BP3 in Cancer (UCLA Case No. 2023-215)
UCLA researchers in the Department of Pathology and Laboratory Medicine have developed small molecules which inhibits the protein IGF2BP3, a highly expressed oncofetal protein in certain cancers, especially in B-acute lymphoblastic leukemia. BACKGROUND: Cancer remains the second leading cause of death in the U.S. Advancements in targeted therapies...
Published: 7/17/2025   |   Inventor(s): Dinesh Rao
Keywords(s): blood cancers, Cancer, cancer inhibition, leukemia
Category(s): Therapeutics > Oncology
Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)
UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...
Published: 7/17/2025   |   Inventor(s): Roger Lo
Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
1 2 3 4 5 6 7 8 9 10 ...